The global Atrophic Vaginitis Treatment Market garnered a market value of USD 2.57 Billion in 2022 and is expected to accumulate a market value of USD 6 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033.
Growth of the atrophic vaginitis treatment market can be attributed to increasing prevalence of the condition, the rising geriatric population, and the growing awareness about the importance of women's health. The market for atrophic vaginitis treatment registered a CAGR of 4.1% in the historical period 2018 to 2022
Atrophic vaginitis is a medical condition that occurs due to the thinning and inflammation of the vaginal walls, which is common in postmenopausal women. Atrophic vaginitis treatment market refers to the market for medications and therapies used to treat this condition.
The atrophic vaginitis treatment market includes a variety of products such as estrogen creams, vaginal moisturizers, and lubricants, among others. These products help to alleviate symptoms such as vaginal dryness, itching, and pain during intercourse.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 2.78 Billion |
| Anticipated Forecast Value (2033) | USD 6 Billion |
| Projected Growth Rate (2023 to 2033) | 8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Atrophic vaginitis treatment reflected a value of 8% during the historical period, 2018 to 2022.
The market was driven by the increasing prevalence of atrophic vaginitis, the rising awareness of women's health, and the availability of effective treatment options.
In addition, the increasing prevalence of atrophic vaginitis, the growing geriatric population, and the availability of new and innovative therapies is shaping the landscape for atrophic vaginitis treatment market.
Thus, the market for Atrophic vaginitis treatment is expected to register a CAGR of 4.1% in the forecast period 2023 to 2033.
Increasing prevalence of atrophic vaginitis along with rising awareness about women's health driving growth of market
The prevalence of atrophic vaginitis is increasing worldwide, especially in postmenopausal women. The condition affects approximately 50% of postmenopausal women, which is a significant population size.
As the global population continues to age, the number of women affected by atrophic vaginitis is expected to increase. Women over the age of 65 are more likely to experience the condition.
There has been a growing awareness about the importance of women's health, leading to increased diagnosis and treatment of atrophic vaginitis.
There are several effective treatment options available for atrophic vaginitis, such as estrogen creams, vaginal moisturizers, and lubricants. The availability of these treatments has increased demand for atrophic vaginitis treatment.
The increasing healthcare expenditure globally has led to increased access to healthcare services, including diagnosis and treatment of atrophic vaginitis.
Availability of Effective Treatment Options spurring growth of atrophic vaginitis treatment market
Estrogen Therapy: Estrogen therapy is one of the most effective treatments for atrophic vaginitis. It can be administered in the form of pills, creams, rings, or patches. Estrogen therapy can help to restore the vaginal tissues and alleviate symptoms such as vaginal dryness, itching, and pain during intercourse.
Vaginal Lubricants: Vaginal lubricants are used to reduce friction during intercourse and alleviate symptoms of vaginal dryness. They can be used alone or in combination with other treatments.
Vaginal Moisturizers: Vaginal moisturizers are used to hydrate and soothe the vaginal tissues. They can be used on a regular basis to alleviate symptoms of vaginal dryness.
Topical Estrogen Creams: Topical estrogen creams can be applied directly to the vaginal tissues to alleviate symptoms of atrophic vaginitis.
Osphena: Osphena is a non-estrogen prescription medication that can help alleviate symptoms of vaginal dryness and pain during intercourse.
Laser Therapy: Laser therapy is a new treatment option for atrophic vaginitis. It involves the use of laser technology to stimulate the growth of new tissue and improve the health of the vaginal tissues.
Principal Consultant
Side effects of hormone therapy along with cost of treatment derailing market growth
While hormone therapy is one of the most effective treatments for atrophic vaginitis, it can have potential side effects such as blood clots, stroke, and breast cancer. This can limit the use of hormone therapy, particularly in women who have a history of these conditions.
Despite growing awareness about women's health, many women may not be aware of the symptoms of atrophic vaginitis or the available treatment options. This can lead to underdiagnosis and undertreatment of the condition.
Some women may prefer to use alternative treatments such as herbal remedies or supplements, which may not have been adequately studied for their efficacy and safety in treating atrophic vaginitis.
Some of the treatment options for atrophic vaginitis can be expensive, and not all women may have access to healthcare coverage that covers these costs.
Due to the intimate nature of the condition, some women may feel embarrassed or uncomfortable discussing their symptoms with their healthcare providers, which can lead to delays in diagnosis and treatment.
Availability of effective treatment favoring growth of market in North America
The North America atrophic vaginitis treatment market is a significant market, primarily driven by the high prevalence of the condition in the region. The market comprises the United States and Canada, which are expected to have a significant demand for atrophic vaginitis treatments.
The United States has a large population of postmenopausal women, which is the most susceptible group for atrophic vaginitis. As a result, the country has a significant demand for treatment options.
The market is also supported by the presence of major pharmaceutical companies, such as Pfizer, Inc., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd, that offer a range of atrophic vaginitis treatments.
In addition, the increasing awareness about women's health and the availability of effective treatment options are expected to drive the growth of the North America atrophic vaginitis treatment market.
Thus, North America is expected to possess 48% market share for atrophic vaginitis treatment market in 2023.
Presence of pharmaceutical companies boosting growth of market in Europe
The Europe atrophic vaginitis treatment market is a significant market, primarily driven by the high prevalence of the condition in the region. The market comprises the major countries in Europe, including the United Kingdom, Germany, France, Italy, Spain, and the rest of Europe.
The increasing aging population in Europe, particularly in Western Europe, is expected to contribute significantly to the growth of the market. Postmenopausal women, who are the most susceptible group for atrophic vaginitis, form a significant proportion of the aging population in Europe.
The market is also supported by the presence of major pharmaceutical companies that offer a range of atrophic vaginitis treatments, such as Pfizer, Inc., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.
Overall, the Europe atrophic vaginitis treatment market is expected to grow at a steady rate, driven by the increasing prevalence of the condition and growing demand for effective treatment options.
The market is also likely to benefit from ongoing initiatives to raise awareness about women's health and the availability of treatment options. Thus, Europe is expected to possess 43% market share for atrophic vaginitis treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of different estrogen-based therapy driving the growth of segment
Estrogen-based therapy is one of the most effective treatment options for atrophic vaginitis because it addresses the underlying cause of the condition.
Atrophic vaginitis is primarily caused by a decrease in estrogen levels in the body, which can lead to vaginal dryness, itching, burning, and pain during sexual intercourse. Estrogen therapy helps to restore estrogen levels, which can improve the health of the vaginal tissues and relieve symptoms.
There are several forms of estrogen-based therapy available for atrophic vaginitis, including vaginal creams, tablets, rings, and patches.
These products deliver estrogen directly to the vaginal tissues, which can help to restore vaginal health and relieve symptoms such as vaginal dryness, itching, and discomfort.
Estrogen therapy has been shown to be safe and effective for the treatment of atrophic vaginitis in numerous clinical studies. It is generally well-tolerated, and side effects are usually mild and temporary. Thus, by therapy type, estrogen based therapy is expected to possess 53% market share for atrophic vaginitis treatment market.
Key players in the atrophic vaginitis treatment are Shionogi, Duchesnay, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex, Endoceutics, Inc.
Duchesnay is a pharmaceutical company that has developed a treatment for atrophic vaginitis called Osphena (ospemifene). Osphena is a selective estrogen receptor modulator (SERM) that helps to restore estrogen levels in the vaginal tissues.
Hormos Medical is a biopharmaceutical company that has developed a treatment for atrophic vaginitis called TX-004HR (Intrarosa in the United States).
TX-004HR is a vaginal insert that contains the hormone dehydroepiandrosterone (DHEA), which is converted into estrogen in the body. The active ingredient in TX-004HR, DHEA, helps to restore vaginal health by increasing estrogen levels in the vaginal tissues.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 2.78 Billion |
| Market Value in 2033 | USD 6 Billion |
| Growth Rate | CAGR of 8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Diagnosis, Treatment, Therapy Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Shionogi; Duchesnay; Hormos Medical; QuatRx Pharmaceuticals; Pantarhei Bioscience; Mithra Pharmaceuticals; AMAG Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc; Theramex; Endoceutics, Inc. |
| Customization | Available Upon Request |
The CAGR for the market is 8% until 2033.
From 2018 to 2022, the market expanded at a 4.1% CAGR.
North America to hold 48% market share in 2023.
Shionogi, Duchesnay and Hormos Medical are key players.
Innovative therapies and expanding aging population present growth prospects.
1. Executive Summary | Atrophic Vaginitis Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 5.1. Pelvic exam 5.2. Urine test 5.3. Acid balance test 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Vaginal moisturizers 6.2. Water-based lubricants 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 7.1. Estrogen based drugs 7.2. Non-estrogen based drugs 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacy 8.2. Online Pharmacy 8.3. Retail Pharmacy 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. MEA 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Shionogi 19.2. Duchesnay 19.3. Hormos Medical 19.4. QuatRx Pharmaceuticals 19.5. Pantarhei Bioscience 19.6. Mithra Pharmaceuticals 19.7. AMAG Pharmaceuticals 19.8. Bayer HealthCare Pharmaceuticals Inc. 19.9. Theramex 19.10. Endoceutics, Inc. 20. Research Methodology
Explore Healthcare Insights
View Reports
Atrophic Vaginitis Treatment Market
